Think of Nesina as a "Me Too" Similar to Januvia, Onglyza, and Trajenta

Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of "gliptins" for treating type 2 diabetes.

Nesina is the latest "me too" diabetes drug to hit the market.

Think of it as another Januvia (sitagliptin), Onglyza (saxagliptin), or Trajenta (linagliptin).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote